Ymabs
Founded 2015 · 54 employees on LinkedIn · 1 known investors
Y-mAbs develops radioimmunotherapy and antibody-based therapies targeting pediatric and adult cancers, with a heritage in high-risk neuroblastoma and expansion into additional oncology indications.
Founders & leadership
Ymabs was founded in 2015 by Thomas Gad.
TG
Thomas GadFounder, Vice Chairman of the Board of Directors, and Chief Business Officer
Investors · 1
Competitors · 2
by search overlap
Robinhood16 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits14 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies competing with Ymabs for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Ymabs do?
- Y-mAbs develops radioimmunotherapy and antibody-based therapies targeting pediatric and adult cancers, with a heritage in high-risk neuroblastoma and expansion into additional oncology indications.
- Who founded Ymabs?
- Ymabs was founded by Thomas Gad in 2015.
- Who are Ymabs's investors?
- Ymabs's investors include Sofinnova Ventures.